Monday, March 31, 2014

Immunotherapy Penn Receives FDA breakthrough therapy designation for ALL treatment

Tags
Immunotherapy Penn Receives FDA breakthrough therapy designation for ALL treatment -

At the University of Pennsylvania developed a personalized immunotherapy has been awarded the designation of breakthrough therapy from the US Food and Drug Administration for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). The experimental treatment, known as CTL019 is the first personalized cell therapy for the treatment of cancer to receive this important classification.

In clinical trials at an early stage of the hospital of the University of Pennsylvania and Children's Hospital of Philadelphia, 89 percent of all patients who did not respond to conventional treatments in complete remission after receiving CTL019.

"Our early results show great promise for a desperate group of patients, many of whom were able to return to their normal school life and work after receiving this new, personalized immunotherapy" said the head of the Penn research team Carl June, MD , Professor Richard W. Vague in immunotherapy in the department of pathology and laboratory Medicine at the Perelman school of Medicine and Director of translational research in the Abramson Cancer Center of the University of Pennsylvania. "Receiving FDA Designation breakthrough is a key step in our work with Novartis to develop this therapy to patients throughout the world who desperately need new options for help fight against this disease. "

breakthrough therapy designation from the FDA, created in 2012, aims to accelerate the development and review of new drugs - drugs and biological agents - that treat serious or life-threatening conditions, if the therapy demonstrated a substantial improvement over available treatments. The FDA has already granted Therapy Breakthrough only four other biological agents.

In August 2012, Penn announced an agreement for research and exclusive worldwide agreement with Novartis to study, develop and market custom chimeric antigen receptor (CAR) T cell therapies for the treatment of cancers. Tests with CTL019 began in summer 2010 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL), and are now underway for adult and pediatric patients with ALL, and patients with non-Hodgkin lymphoma myeloma. Penn and Novartis are also working on the next generation of CAR therapies, with trials for mesothelioma, ovarian, breast and pancreatic cancer at an early stage now.

During the 2013 annual meeting of the American Society of Hematology, the Penn research team announced the results of the study of the first 27 all patients (22 children and five adults) treated with CTL019 89 percent of patients had a complete response to therapy. The first pediatric ALL patient receiving the therapy Penn celebrated the second anniversary of his remission of cancer in May, and the first adult patient remains in remission a year after receiving the therapy.

The experimental treatment developed by the Penn team begins by removing T cells from the patient through a similar process of apheresis blood donation and genetically reprogram the cell Penn clinical and vaccine production facilities. After infused back into the patients body, these new cells built "hunters" to both multiply and attack targeting tumor cells that express a protein called CD19. Tests reveal that the army of hunters cells can reach more than 10,000 new cells for each single modified cells of patients receive.

The adult CTL019 all trials at the University of Pennsylvania Abramson Cancer Center are directed by David Porter, MD , Jodi Fisher Professor Horowitz care excellence leukemia and director of the blood and marrow transplant in the Abramson Cancer Center and Noelle Frey, MD, MSCE , assistant professor of medicine at the Abramson Cancer Center. Pediatrics All tests are conducted by Stephan Grupp, MD, PhD , professor of pediatrics and director of translational research in the Center for Research on Early Childhood cancer at the Hospital of Philadelphia children . Bruce Levine, PhD , Barbara and Edward Netter Professor in cancer gene therapy in the Department of Pathology and Laboratory Medicine, is leading clinical cell Penn and vaccine production facilities.

Sunday, March 30, 2014

Researchers identify new genes that likely contribute to asthma

Tags
Researchers identify new genes that likely contribute to asthma -

In a study published yesterday in the journal Nature Immunology , a group the La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new genes that likely contribute to asthma, a disease that currently affects over 0 million people worldwide.

genetic material of an organism, also known as its genome can be divided into smaller sections or "neighborhoods". Scientists can determine which genetic neighborhoods in a cell are active, or prepared for the production of genes by looking for a marker on the genome called amplifier. An amplifier can increase the production of genes in its immediate vicinity. The purpose of the published study is to find genes whose neighborhoods are active in diseased cells but inactive in healthy cells. Genes that are active in areas in diseased cells may contribute to disease, and can potentially be targeted with medication.

In order to find genetic neighborhoods that are active in the asthmatic disease, scientists in the development of the group Vijayanand experiences on memory cells that develop abnormally in patients 'asthma. The memory cells are loaded quickly respond to foreign substances called antigens that the host has been previously discussed. portion of inflammation of the air, which characterizes asthma, is mediated by a hyperactive response to inhaled antigens by the memory cells.

Applying the technique of small populations of abnormal memory cells, Vijayanand shows 33 genetic areas which are very active in the cells sick, but inactive in healthy cells, moving the research center on asthma specific genes that are located in these districts.

The genome-wide association studies (GWAS) that are less accurate, have already identified 1,500 potential target areas associated with asthmatic disease. According Vijayanand, these objectives are too many to study individually, and therefore, the field remained focused on a few molecules to discover new treatments for asthma. With their approach, Vijayanand team investigated the 1500 targets for those most likely to contribute to asthmatic disease. "Our unbiased approach and without hypothesis revealed an impressive but manageable number of new molecules that could play a role in asthma and potentially new therapeutic targets," said Vijayanand.

Vijayanand and his team completed the study using different amounts of cells from the blood of healthy subjects and patients with asthma. They did to determine the smallest number of cells that were necessary for their technique, and found that it works with as little as 10 000 cells, which is significantly less than the millions of cells needed for the use other methods. Vijayanand contemplates the use of this technique in situations where access is limited to cells, such as tumor biopsy for cancer.

The prevalence of asthma is increasing in the developed world, and in several large developing countries. Treatment of asthma will generally include non-specific drugs to long term, because there is no cure at present.

Vijayanand said this study provides information that can be the starting point of many tracks of research and treatment. He said, "Our study provides a rich and comprehensive resource that will be useful to the scientific community, allowing investigators to conduct their own detailed study of the functional significance of new genes and enhancers that we have identified."

the results were published in a document entitled Nature Immunology "epigenomic analysis of primary human T cells reveals activators associated with the differentiation of TH2 memory cells and asthma susceptibility." the study was funded in part by the national Institutes health under grant numbers R01 HL114093 and U19 AI100275.

the researchers from other institutions also contributed to this study, including the Southampton National Institute for research and University Health California, San Francisco.

Saturday, March 29, 2014

Regeneron, Sanofi report positive results from Phase 2b study dupilumab with moderate to severe AD

Tags
Regeneron, Sanofi report positive results from Phase 2b study dupilumab with moderate to severe AD -

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi (EURONEXT: SAN and NYSE: SNY ) announced today positive results of a dose ranging study phase 2b dupilumab, an experimental treatment in patients adults with moderate to severe atopic dermatitis (AD), a severe form, chronic eczema. All dupilumab doses have reached the primary endpoint of a greater improvement in Eczema Area Severity Index (EASI) Baseline scores compared to placebo. In addition, the companies also announced that four clinical studies of previous dupilumab in moderate to severe atopic dermatitis were published today in the New England Journal of Medicine (NEJM). Dupilumab is an investigational monoclonal antibody that blocks the signaling of IL-4 and IL-13, cytokines that play a key role in the pathogenesis of moderate to severe atopic dermatitis.

"These clinical data, coupled with our Phase 2a results in asthma last year, support the scientific evidence increasingly as IL-4 / IL-13 pathway may be a fundamental factor in allergic diseases, "said George D. Yancopoulos, MD, Ph. D., Chief scientific Officer of Regeneron and President of Regeneron Laboratories. "Blocking the IL-4 / IL-13 signaling may provide an important new approach for atopic conditions including asthma, atopic dermatitis and nasal polyposis, where we have clinical programs underway."

In the Phase 2b trial, all five subcutaneous doses of dupilumab showed a dose-dependent improvement in the primary endpoint, the percent change in the average baseline EASI score at week 16 . improvements in EASI score ranged from a high of 74 percent for patients in the group receiving the highest dose, which received 300 milligrams (mg) per week, a minimum of 45 percent in patients who have received the lowest dose of 100 mg per month, compared with 18 percent for patients in the placebo group (p <0.0001 for all doses).

The most common adverse event (AE) in the Phase 2b study were nasopharyngitis, which was balanced across treatment groups dupilumab (18.5 to 23 percent) compared to placebo (21 percent). reactions at the injection site were more frequent in the group dupilumab (5 to 9.5 percent) compared to placebo (3 percent), as was headache (12 to 15 percent) compared to placebo (8 percent).

dupilumab-treated patients showed a statistically significant and dose-dependent improvement in other key efficacy measures compared to placebo after 16 weeks of treatment:

  • 12 percent to 33 percent of patients treated with dupilumab compensation or almost clearing the skin lesions as measured by global assessment (IGA) score a investigator of 0 or 1, compared to 2 percent with placebo. (P = 0.02 to P <0.0001)
  • dupilumab patients treated experienced a 16.5 percent to 47 percent average reduction in itch as measured by pruritus numerical rating scale (NRS) score compared with an increase of 5 percent in the placebo group. (P = 0.0005 p <0.0001)

"Atopic dermatitis is known to have a profoundly negative effect on quality of life and people with more severe forms of this disease have limited treatment options, "said Elias Zerhouni, MD, President, global R & D, Sanofi." These results are consistent with what was observed in previous clinical studies and add to the body of evidence that experimental dupilumab may have a role in patients with moderate to severe atopic dermatitis. We are now able to select the optimal dose for the phase 3 studies, we plan to begin later this year. "

this Phase 2b, double-blind, placebo-controlled, 16-week, the dose ranging study randomized 380 patients with moderate to severe atopic dermatitis, which could not be adequately controlled with topical medications or where a topical treatment was not advised. Patients were randomized to receive one of five doses of dupilumab (300 mg per week, 300 mg every two weeks, 300 mg per month, 0 mg every two weeks, 100 mg per month) or placebo. Patients in the study had about 50 percent of their skin affected by atopic dermatitis at baseline. In the past year, about 35 percent of patients received oral corticosteroids and about 20 percent received a non-steroidal systemic immunosuppressant for AD. About 60 percent of patients had another allergic condition, about 40 percent of patients who had a history of asthma. The period of follow-up study is underway and patients will be followed for 16 weeks after treatment.

The NEJM dupilumab moderate to severe atopic dermatitis Publication
The New England Journal of Medicine publication includes data from four placebo-controlled studies, which all evaluated doses weekly subcutaneous of dupilumab. This included a 12-week study of Phase 2a monotherapy, a phase 2a, four weeks dupilumab study in combination with topical glucocorticoid and two Phase 1 monotherapy four weeks. In these studies, the most common adverse events were nasopharyngitis and headache, which occurred with a higher frequency in the dupilumab group. Dupilumab treatment, either as monotherapy or in combination, was associated with improvement of skin lesions and substantial improvements in pruritus (itching). The full publication is available at www.nejm.org.

"The New England Journal of Medicine publication brings important attention to the moderate to severe atopic dermatitis, a condition common, chronic skin condition characterized by severe itching that can have a significant negative impact on the ability of a patient to lead full and active lives, "said Lisa Beck, MD, Department of Dermatology, University of Rochester Medical Center and lead author of the NEJM paper." We are encouraged by the consistent results in these earlier studies and have look forward to further clinical research with dupilumab. "

Friday, March 28, 2014

CF102 drug-Fite Can gets approval in Israel for the patient with hepatocellular carcinoma

Tags
CF102 drug-Fite Can gets approval in Israel for the patient with hepatocellular carcinoma -

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a proprietary drug pipeline to small molecules that target inflammatory diseases and cancer, today announced that the Israeli Ministry of Health (MOH) approved the use of its CF102 drug for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the Compassionate use Program in the country. The program allows physician to the unique initiative of access of patients to experimental treatments for innovative products or research not yet registered in any country in the world. Can Fite has also previously received orphan drug designation from the Food and Drug Administration of the United States for CF102 in the treatment of advanced hepatocellular carcinoma.

This patient was previously enrolled in the phase of Can-Fite I / II dose-escalation study of liver cancer in Israel and was successfully treated with CF102 for about 5 years. Data from the completed Phase I / II study demonstrated a very favorable safety profile, lack of hepatotoxicity, stabilization of disease in 22% of patients, prolonged survival time compared to placebo and regression tumor metastasis skin.

on the basis of these encouraging results, Can-Fite began a comprehensive phase II trial for CF102 as a second-line treatment of advanced hepatocellular carcinoma (HCC) with Class Child-Pugh B cirrhosis patients who have failed Nexavar (sorafenib), which is FDA-approved drug for the treatment of hepatocellular carcinoma. The phase II study will be conducted in the United States, Europe and Israel with 78 subjects to be dosed with CF102. The study protocol was approved by Israel and the United States, and approval is expected from the European Union.

According to Global Industry Analysts, the global cancer liver drug market is expected to exceed $ 2 billion by 2015.

"We are so pleased that the Ministry of Health given the continued use of CF102 in the Program on the use of compassion for this patient who seems to have benefited greatly from our drug. Before enrolling in our Phase I / II study, patients had undergone all other treatments approved and they managed to stop the progression of the disease. we are told by his doctor that he is strong and stable health and we wish her well being, "said Can-Fite CEO Dr. Pnina Fishman. "We believe that the very favorable safety data from our Phase I / II trial may have been a key factor in the decision of the Ministry of Health to approve CF102 for compassionate use."

Thursday, March 27, 2014

New medical center professional online video Mayo Clinic

Tags
New medical center professional online video Mayo Clinic -

Mayo Clinic is doing its complete video largest medical education lectures and presentations on recent clinical innovations in patient care, education and research accessible to other health professionals in the new center-line health care video.

These lectures contain practical new procedures, treatment options and research covering a wide variety of specialties. For example, a video conference on C-11 choline treatment for recurrent prostate cancer describes the benefits for patients, as well as production, imaging and treatment facilities necessary for treatment. Another, fecal microbiota transplant, provides step by step details of how the procedure is completed so that providers and patients can see the process from start to finish.

"In addition to serving our patients here, we are committed to sharing information with the world of medicine. We develop constantly refining and improving new and better techniques in medicine. We have a moral responsibility to share this information with the broader medical community and allow the distribution through the Professional Video medical Center, "said John T. Wald, MD, medical director for marketing and public affairs, of the Mayo Clinic.

the programs can be found at medprofvideos.mayoclinic.org. health professionals can watch videos describing clinical advances and research in the disease and the processing status, procedures and surgeries. the videos are also available on the website of the National Library of Medicine.

Wednesday, March 26, 2014

UH Case Medical Center named one of the best hospitals in the nation

Tags
UH Case Medical Center named one of the best hospitals in the nation -

University Hospitals (UH) Case Medical Center has again been named one of the best hospitals the country, according to US News & World Report annual ranking of best hospitals . UH Case Medical Center has been ranked in 12 specialties of the methodology of the rankings for the third consecutive year in the Top 20 in four specialties -. Cancer, Gastroenterology, Ear, Nose & Throat Orthopaedics and

Recent data underscore the elite national status of UH Case Medical Center as a leader in clinical care, only 3 percent of the nearly 5,000 hospitals that were analyzed for the 2014-15 best hospitals got the same ranking in a national specialty.

"We are extremely pleased that US News & World Report has again recognized University Hospitals Case Medical Center as one of the largest academic medical centers in America," says Fred C. Rothstein , MD, President, UH Case Medical Center. "We are proud to be recognized nationally for his extraordinary commitment to quality, safety and best practices in patient care."

The US News Best Hospitals annual rankings now in their 25th year, recognize hospitals that excel in treating patients with the most difficult medical conditions UH Case medical Center is nationally ranked in.

  • Cancer ( # 18 )
  • cardiology and cardiac surgery ( # 22 )
  • Diabetes & Endocrinology ( # 38 )
  • Ear, Nose & Throat ( # 18 )
  • Gastroenterology & GI Surgery ( # 14 )
  • Geriatrics ( # 28 )
  • Gynaecology ( # 47 )
  • Nephrology ( # 29 )
  • neurology and neurosurgery ( # 23 )
  • Orthopaedics ( # 17 )
  • Pneumology ( # 36 )
  • Urology ( # 30 )

Furthermore, UH Case Medical Center ranked No. 2 in the Ohio State and No. 2 in the metropolitan area of ​​Cleveland. University Hospitals Geauga Medical Center Ranked # 8 in Cleveland Metro area rankings and was also praised for high performance in six specialties, including :. Gastroenterology & GI surgery, geriatrics, neurology and neurosurgery, orthopedics, pulmonology and urology

US News publishes the best hospitals to help guide patients who need a high level of care because they face the particularly difficult surgery, a challenging condition, or added risk because of age or multiple health problems. Objective measures such as survival and security of patient data, adequacy of nurse staffing levels and other data largely determined the rankings in most specialties.

The specialty rankings and data were produced for US News by RTI International, a leading research organization based in Research Triangle Park, North Carolina using the same data, US News has produced the ranking state and metro

"data tell the story. - a hospital that has emerged from our analysis that one of the best has much to be proud," said US News Health Editor rating Avery Comarow. "Better Hospital has demonstrated its expertise in treating the most difficult patients."

Tuesday, March 25, 2014

Study: Fish oil supplements reduce cognitive decline, brain atrophy in older people

Tags
Study: Fish oil supplements reduce cognitive decline, brain atrophy in older people -

Alzheimer's disease affects more than 5 million every year US

Rhode Island the hospital researchers completed a study that found regular use of fish oil supplements (FOS) was associated with a significant reduction in cognitive decline and brain atrophy in older people. The study examined the relationship between the FOS used in the Alzheimer Neuroimaging Initiative diseases (ADNI) and indicators of cognitive decline. The results are published online ahead of print in the journal Alzheimer's and dementia .

"At least one person is diagnosed every minute with the disease (AD) Alzheimer's and despite all efforts, we have not yet found a cure for this widespread and debilitating disease," said lead researcher Lori Daiello, PharmD, of Alzheimer's disease and memory disorders Center at Rhode Island hospital. "the field is currently engaged in numerous studies to find better treatments for people with AD ;. However, looking for ways to prevent AD or slow cognitive decline in normal aging is of utmost importance "

In this retrospective study, older people involved in the ADNI study was assessed with . neuropsychological tests and brain magnetic resonance imaging (MRI) every six months the group included 229 elderly who were cognitively normal, 397 who were diagnosed with mild cognitive impairment, and 193 with AD

the study found that fish oil supplements use of during the study was associated with significantly lower rates of cognitive decline as measured by disease Alzheimer's disease assessment Scale ( ADAS-cog) and the Mini Mental State Exam (MMSE), but this benefit was observed for the group of participants without dementia at the time of registration.

"Furthermore, the imagery cerebral series conducted during this study showed that participants with normal cognition who reported taking fish oil supplements showed less brain shrinkage in key neurological areas, compared to those who do not use supplements, "said Daiello. "In addition, the positive results on cognitive tests and brain MRI were observed in people who do not carry the genetic risk factor best studied for AD, APOE-4. More research is needed, but these results are promising and underscore the need for future studies to expand the current knowledge of the effects of FOS use on cognitive aging and AD. "

It is estimated that over 5 million people in the United States have Alzheimer's disease. It is the most common form of dementia and is the sixth leading cause of death in the United States

Monday, March 24, 2014

Isis wins $ 1 million payment from GSK related to the advancement of ISIS-TTRRx

Tags
Isis wins $ 1 million payment from GSK related to the advancement of ISIS-TTRRx -

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today ' hui she won a stage of $ 1 million payment from GlaxoSmithKline (GSK) related to the progress of the phase 2/3 ISIS-TTR Rx in patients with amyloid polyneuropathy family (FAP).

ISIS-TTR Rx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve / or cardiac tissues. Including this milestone payment, Isis has generated $ 27 million in upfront and milestone payments for advancing ISIS-TTR Rx . This milestone payment of $ 1 million is the fifth of the nearly $ 58 million in payments Isis step is eligible to win the Phase 2/3 study progresses. Additionally, if GSK chooses to exercise its exclusive option ISIS-TTR Rx program, Isis is eligible to receive royalties, payments and regulatory steps in sales and double-digit royalties on sales of ISIS TTR Rx .

The Phase 2/3 ISIS-TTR Rx is a double-blind, placebo-controlled, randomized international study designed to support a marketing authorization application market ISIS-TTR Rx in patients with FAP. The fifteen-month study will measure the effects of ISIS-TTR Rx on neurological dysfunction and on quality of life. ISIS-TTR Rx is an investigational drug that is designed to inhibit the production of all forms of TTR and treat all types of transthyretin amyloidosis related. For more information about the study, please visit www.clinicaltrials.gov and search for NCT01737398 ID.

Sunday, March 23, 2014

UH Case Medical Center signed an agreement with ARUP to offer HIV testing DEEPGEN-

Tags
UH Case Medical Center signed an agreement with ARUP to offer HIV testing DEEPGEN- -

University Hospitals (UH) Case Medical Center has signed an agreement with ARUP Laboratories, national major clinical reference laboratory that offers an extensive menu of very complex and unique medical tests in hospitals, medical schools and other nonprofit organizations and business in the United States.

under the agreement, ARUP will include in its menu of tests of an HIV diagnostic test invented in Translational Laboratory University Hospital Miguel Quinones-Mateu, PhD, Scientific Director Laboratory and assistant professor at UH Department pathology, school of medicine of Case Western Reserve University.

retesting DEEPGEN HIV, monitoring the success of HIV treatment by determining drug resistance and the ability of the virus to infect different cell based deep genetic sequencing. ARUP, a non-profit company of the University of Utah, DEEPGEN include in its menu of tests and nationally on the test market. Clinical specimens will then be called UH Translational Laboratory in Cleveland all 50 states.

DEEPGEN HIV provides a significant platform for physicians and HIV researchers, both in academia and industry. The test allows the detection of minority variants unimaginable frequencies with HIV genotypic current based test (Sanger) sequencing standard.

"Although the clinical relevance of these minority members of the viral population is still under debate, it is reasonable to assume that sooner these mutant viruses are detected, the sooner the right strategy can be defined for control their growth, "said Dr. who the Mateu." DEEPGEN HIV is now genotyping test primary HIV used by HIV doctors at Case Western Reserve University / University Hospitals AIDS Clinical Trials Unit and we analyzed clinical samples from other institutions in the region. This agreement with ARUP will accelerate the use of this innovative and highly sensitive test nationwide, which will allow us to improve the care and treatment of people infected with HIV across the country. "

" I am very pleased with our relationship with ARUP, as it seems to be a natural synergy that we both can leverage to develop the quality of diagnostics and care for patients with HIV nationally, "said Ronald E. Dziedzicki, COO at UH Case Medical Center.

"Our relationship with UH Case Medical Center enables ARUP to offer this innovative test to our clients for the management of patients with HIV," said Jerry Hossong, MD, DDS, director and director of medical laboratories of ARUP. "We are very pleased to include this test as part of our comprehensive menu of services."

Saturday, March 22, 2014

Researchers use the safest method to stimulate ovulation in women undergoing IVF treatment

Tags
Researchers use the safest method to stimulate ovulation in women undergoing IVF treatment -

The researchers successfully used a new and potentially safer method stimulate ovulation in women undergoing in vitro fertilization treatment.

Twelve babies were born after their mothers received an injection of kisspeptin natural hormone for their eggs to mature.

doctors usually administer another hormone, hCG, for this purpose, but in some women, there is a risk that this may overstimulate the ovaries, with potentially deadly consequences.

scientists from Imperial College London and clinicians at Imperial College Healthcare NHS Trust tested the new method in 53 healthy volunteers at Hammersmith Hospital in London. The study, funded by the Medical Research Council, the National Health Research Institute and the Wellcome Trust, is published today in the Journal of Clinical Investigation .

One in six couples in the UK experience infertility, and 48.147 women underwent IVF treatment in 2011.

Ovarian hyperstimulation syndrome (OHSS) affects about a third of patients IVF mildly anemic, causing symptoms such as nausea and vomiting. Less than 10 percent of patients experience moderate to severe OHSS, which can cause kidney failure

Waljit Dhillo Professor, Department of Medicine at Imperial College London, who led the study, declared:. "SHO is a medical major problem. It can be fatal in severe cases and it occurs in women undergoing IVF treatment who are otherwise very healthy. We really need more effective natural triggers for the maturation of eggs during IVF treatment, and the results of this trial are very promising. "

kisspeptin is a natural hormone that stimulates the release of other reproductive hormones within the body. Unlike hCG, which remains in the blood for a long time after an injection, kisspeptin is decomposed more rapidly, which means the risk of hyperstimulation is lower.

Women in the study had a single injection of kisspeptin to induce ovulation. 51 participants developed mature eggs on 53. Forty-nine women had one or two fertilized embryos transferred to the uterus, and 12 became pregnant, which is a good result compared to the standard conventional IVF therapy.

The researchers will now conduct a second study in women polycystic ovaries, which have the highest risk of OHSS.

"Our study showed that kisspeptin can be used as a trigger for physiological maturation of eggs in IVF treatment," said Professor Dhillo. "It was a joy to see 12 healthy babies born using this approach. We will now do more studies to see if kisspeptin reduces the risk of ovarian hyperstimulation in women who are more prone to develop in order to improve the safety of IVF therapy. "

Alison and Richard Harper was a little boy, Owen, in October 2013 after taking part in the trial in January.

" We participated because we wanted to pay forward in back to the people who made it possible for us to have a child by in vitro fertilization, "said Alison

." I went through several cycles of IVF before, but this test was the least uncomfortable - it was less painful and I felt less swollen the staff we met were amazing. ".

Friday, March 21, 2014

A study shows the correlation between education and myopia

Tags
A study shows the correlation between education and myopia -

Education and behavior have a greater impact on the development of myopia than do the genetic factors: With the school year ended, a person becomes more myopic. The higher the education level, the more serious degradation of vision. These are the conclusions drawn by the researchers of the Department of Ophthalmology at the Medical Center of the University of Mainz from the results of the first cohort study based on the population of this condition. A myopic eye is one in which the eyeball is too long compared to the refractive power of the cornea and lens. Therefore, remote objects are displayed on the retina of focus. The eyeball continues to grow in humans until they reach adulthood and this means that myopia can also continue to progress in people who have reached their 30s. It has been shown that both genetic predisposition and environmental stimuli play a role in the development of myopia.

The team of the Department of Ophthalmology at the Mainz University Medical Center led by Professor Norbert Pfeiffer and PD Dr. Alireza Mirshahi found strong evidence that achieving a level of education more high and spend more years in school are two factors associated with a greater prevalence and severity of myopia or nearsightedness. The results of the ophthalmic segment of the study population based Gutenberg Health (GHS) undertaken by the Medical Center of the University of Mainz provides evidence that environmental factors may outweigh genetic factors in the development of myopia . A related article by the Mainz team has just been published in the American Academy of Ophthalmology journal, Ophthalmology .

Myopia is widespread. However, it has become more common worldwide in recent years and has an increasing global health and economic concern. Severe myopia is a major cause of visual impairment and is strongly associated with an increased risk of complications such as retinal detachment, macular degeneration, premature cataracts, and glaucoma. Developed Asia reported an increase in myopia rates of up to 80 percent. The speed of this escalation suggested that environmental factors, such close work such as reading, using a computer, and higher education could play an important role.

To analyze the correlation between the development of myopia and education, researchers at the Mainz University Medical Center examined nearsightedness to 4,658 Germans aged 35-74, excluding any person with cataracts or who had undergone refractive surgery. This research was conducted as part of the Gutenberg on the health study and the results show that myopia becomes more common with higher levels of education. Only 24 percent of myopic subjects were no school or other training, while 35 percent of high school graduates and graduates of vocational schools were myopic. However, no less than 53 per cent of university graduates were myopic.

In addition to the completed education levels, researchers based Mainz also found that people who spent more years in school were found to be nearsighted, nearsightedness with worsening each year from school. In addition, the researchers studied the effects of 45 genetic markers, but found that they have a much lower impact on the severity of myopia with respect to educational attainment.

So what can be done to remedy this situation? It is impossible to nearsightedness "cure"; it can not be corrected with visual aids or surgical intervention to change the refraction parameters. Attempts to slow the progression of myopia with drugs, special glasses or contact lenses have been unsuccessful to date. Recent studies in children and young adults in Denmark and Asia have shown that the risk for the development of myopia may be less to spend more time outside and therefore to greater sun exposure . Fifteen hours per week are recommended, while, at the same time, the eyes must not be used for close-up activities such as reading, watching television or using computers and smart phones for more than 30 hours week. "Since students seem to be at higher risk for myopia, it makes sense to encourage them to spend more time outdoors as a precaution," said Dr. Alireza PD Mirshahi, lead author of the study .

Gutenberg Health Study (GHS) is a prospective study of interdisciplinary-based cohort single-center population, which was conducted at the Mainz University Medical Center since 07. cardiovascular disease, cancer, eye diseases, metabolic disorders, and immune system and mental disorders are being studied as part of the study. The purpose of the study is to improve the prediction of individual risk for these diseases. To this end, lifestyle, psychosocial factors, environmental, clinical laboratory parameters, and severity of any subclinical disorder are considered. A full biorepository is being developed so that molecular biology investigations may be conducted. During the initial visit, 15,010 participants aged 35 to 74 years were invited to participate in a program review of five hours at the study center. This was followed by a computer-assisted telephone interview (CATI) using a standardized questionnaire and assessment of diseases and health problems after 2.5 years. All parameters will be subject to extensive validation. In April 2012, a detailed follow-up review of similar participants to the basic examination was conducted at the center five years after their inclusion in the study. The goal is to continue to follow the cohort and to perform other tests.

Thursday, March 20, 2014

People with schizophrenia more likely to have low levels of vitamin D

Tags
People with schizophrenia more likely to have low levels of vitamin D -

vitamin D deficiency individuals are twice as likely to be diagnosed with schizophrenia as people who have sufficient levels of vitamin, according to a new study published in Journal of the Endocrine Society of Clinical Endocrinology & Metabolism .

Vitamin D helps the body absorb calcium and is necessary for bone and muscle health. The skin naturally produces this vitamin after exposure to sunlight. People also get smaller amounts of vitamins through foods such as milk fortified with vitamin D. More than 1 billion people worldwide are estimated to have deficient levels of vitamin D due to sun exposure limited.

Schizophrenia is a mental illness with symptoms that can include delusions and hallucinations. Since schizophrenia is more common in high latitudes and cold climates, the researchers hypothesized vitamin D may be linked to the disease.

"This is the first comprehensive meta-analysis to examine the relationship between the two conditions," said one of the study authors, Ahmad Esmaillzadeh, PhD, of the University of Isfahan medical sciences in Isfahan, Iran. "When we looked at the findings of several observational studies of vitamin D and schizophrenia, we found that people with schizophrenia have vitamin D levels below that of healthy people. The vitamin D deficiency is quite common among people with schizophrenia. "

The researchers examined the results of 19 observational studies that assessed the relationship between vitamin D and schizophrenia. Overall, the studies focused on vitamin D levels and mental health 2804 adult participants. The studies used blood tests to determine levels of vitamin D each participant.

The meta-analysis found that people with schizophrenia had significantly lower levels of vitamin D in the blood compared to control groups. The mean difference in vitamin D levels between schizophrenia patients and control participants was -5.91 ng / ml. People with vitamin D deficiency were 2.16 times more likely to have schizophrenia than those with sufficient vitamin D in their blood. In addition, 65 percent of participants who had schizophrenia also were vitamin D deficient.

"There is a growing trend in the field of nutrition science to consider vitamin D and its relation to conditions such as diabetes, cancer, heart disease and depression" Esmaillzadeh said. "Our results support the theory that vitamin D may have a significant impact on mental health. More research is needed to determine how the increasing problem of vitamin D deficiency can affect our overall health."

Wednesday, March 19, 2014

dynamic nuclear polarization: An Interview with Professor Robert Griffin, Massachusetts Institute of Technology

Tags
dynamic nuclear polarization: An Interview with Professor Robert Griffin, Massachusetts Institute of Technology -

Interview by , M.Sc.

Professor Robert Griffin
THOUGHT lEADERS SERIES ... overview of the world's foremost experts

Can give you a brief introduction to you and your work on dynamic nuclear polarization?

I am Professor Robert Griffin and I teach physical chemistry at the Massachusetts Institute of Technology. We worked on the dynamic nuclear polarization (DNP) for almost 30 years now, since 1986, when we received our first NIH Grant to build the necessary equipment to DNP.

Can you explain briefly how DNP works?

DNP, or dynamic nuclear polarization, is an NMR technique that transmits a polarization of the electron spins of the nuclear spins, using a constant irradiation by microwave to allow the transfer.

Since the spin polarization amplitude in electrons can be much greater than in the core, effectively stimulates the nuclear spin polarization of the way above the sample you see at thermal equilibrium under normal conditions NMR

it makes NMR measurements much more sensitive. - Something 20 times, 100 times better, which allows us to see details in the molecular structures which require incredibly high field spectroscopy of conventional NMR.

Bruker - Bob Griffin

How DNP was first developed?

using DNP was proposed by Albert Overhauser in the first experiment using the technique 1950 was conducted in the Department of Physics at the University of Illinois by Charlie Slichter and his pupil Tom Carver.

They irradiated lithium metal with low-frequency microwave, using a very small field of about 30 Gauss, because electronic devices are very easy to deal with this frequency.

everyone was very excited about it and in the 1960s and the late 1970s, people began to try to make DNP at higher and higher frequencies, that they obtained with modest success.

was really the problem they used solutions, often aqueous solutions, and there was a lot of dielectric heating from the microwave -. like when you heat a cup of coffee in the microwave oven

There were many technical problems related to this.

Meanwhile, superconducting NMR magnets have been introduced which means that if you are going to use DNP you had to have higher frequencies than microwave available.

Until recently, when we started working on DNP, you can only buy commercial microwave sources, which limits you to 60 MHz for proton NMR and that is simply not very interesting for people today.

when we arrived in DNP, I made a decision and argued that if we were going to do it, so we needed to develop microwave sources that allow us to go up the frequencies used in contemporary NMR experiments.

would mean 400 MHz first, then 0, 800, and finally up to the 1.2 GHz NMR fields that will be produced by Bruker in the near future.

We then made a big investment in technology. We decided that we needed a source of microwave gyrotron and fortunately be at a place like MIT, my colleague Richard Temkin who was in the street, knew how to build a gyrotron.

What we have next door was assembling a system that operates at 211 MHz using a 140 GHz gyrotron. This was the first DNP spectrometer and is still in fact operate as a DNP spectrometer high frequency today. This is more or less at the origin of DNP.

What are the main stages of development of DNP?

The first major step was actually obtain the gyrotron 140 GHz and 211 MHz spectrometer associated with work. It was a very important step for us and in 1993 we published the first article on this in Physical Review Letters .

This document describes using a radical called "BDPfA" we put in polystyrene. However, all this was paid by the NIH and they are not very interested in a chemical polymer such as polystyrene; they really wanted to polarize proteins.

A few years later, in 1995, we finally got something running that could be applied to proteins and that was another important step. We thought you could use the free radicals in the water soluble TEMPO to polarize water and glycerol solutions achieve very improvements. We achieved an improvement of 180, which is quite respectable even by today's standards.

At this point, even though we had a gyrotron operation, it was actually a home device that was very difficult to use and really could do so for about 30 minutes or an hour if we were lucky. After that he had to turn off to let it "rest" for a while and let his empty recover.

The next important step was thus built a device that has been configured correctly and can pump vacuum very well. This gyrotron behind us, for example, generally operates at a pressure of 10 -8 and preferably 10 -9 or 10 -10 Torr.

We built a new tube of 250 GHz which actually works continuously. We ran for almost ten years, and then there was a vacuum breakdown, but we have since put it back together and it has been operating very well for about six or eight months now continuously.

Get a source of microwave gyrotron that was very stable and relatively easy to use, really was an important step in the next stage of development of technique and allowed us to begin to record spectra proteins.

in 08 and 09, we published a part of the very first really nice DNP improved spectra of bacteriorhodopsin, which is a very famous membrane protein.

The next step was to take the 250 GHz (or 380 MHz for protons), which is still a very small field for NMR to 0, 700 or 800 MHz. We then built a 460 GHz gyrotron which corresponds to a field of 700 MHz operating protons and who was the next important step.

Perhaps a fifth milestone was reached a really routine temperature operation, low, which is crucial for DNP as you need a very good temperature stability over long periods of time - about a week. So all these technical achievements have come together to develop and produce the equipment.

Another paramagnetic molecules very, very important part of DNP is to have the form of stable free radicals, which serve as bias source. Some of the most effective polarizing agents have been developed by Kan Hu, a graduate student in the group from 04 to 08, as diradicals. It was a collaborative effort with my colleague Tim Swager, who is an outstanding organic chemist.

We took two TEMPO molecules and tied together. Their electrons interact with each other and they become coupled dipole, which allows us to perform cross experiments DNP effect.

For these experiments, you flip an electron and another electron, which leads to a frequency difference which polarizes the nuclear spin, which is called a crossover effect. This was the biggest improvement in the improvement and sensitivity that we have seen so far.

Paul Tordo and Marseille colleagues recently synthesized a beautiful biradical. It is actually two TEMPO tied together with a urea molecule and is providing us with improvements of 420, which brings us essentially to where we are today.

Chemicals - 50

What impact will DNP have on our daily lives?

Well, DNP probably will not have a direct impact on someone's life, but it will have a significant indirect impact, in that it will allow people to make structural biology experiments they could not even think of doing without it.

For example, at this meeting, we have heard several references to the amyloid proteins that are involved in Alzheimer's disease, Parkinson's disease, type 2 diabetes and related amyloidosis dialysis ... all these terrible diseases related to age that are very, very debilitating and lead to severe dementia.

DNP will probably leave us a much more effective way, is to determine the structures of these amyloid proteins. Once you determine their structure, you can start thinking about drugs that might bind them and inhibit fibril or dissolve fibrils, for example.

There is also another area of ​​DNP called "DNP dissolution, 'in which you polarize a sample at very low temperature and dissolve in water. You then taken to another magnet or you can actually inject into a person and see a picture of a highly polarized compound, such as pyruvate, for example.

This kind of technique is actually used at UCSF in California to diagnose prostate cancer and we become better performing DNP dissolution, I think many new clinical applications will be found for it.

What direction do you see DNP will in the near future?

An easy thing to realize is simply going to higher fields. Currently, we run at 800 MHz and Bruker sold three or four 800 MHz spectrometers, 527 GHz and 1.1 GHz 1.2 machines are on the drawing board.

The obvious thing to do would be to extend the technology to these frequencies. Very important, we also begin to see that it is important to have a polarizing agent adapted to a magnetic field of operation and I think there will be developments and continuous improvements in terms of polarization agents we to use DNP.

Another large area, we and other groups in the United States and Europe to work is "pulsed DNP. All you can do with a CW radiation, you can probably do better with pulses. You can manipulate the spin, you can switch the phases, you can do all sorts of phase cycling experience and to experience much, much more effective.

Thus, in the same way Fourier Transform NMR is a boom in solution and solid state NMR, I think the DNP pulse will likely eventually emerge as the preferred method to perform these experiments

Tuesday, March 18, 2014

Children who experience stress early in life have emotional, physical health problems

Tags
Children who experience stress early in life have emotional, physical health problems -

Children who have been abused or neglected early in life are at risk develop both emotional and physical health problems. In a new study, scientists found that the abuse affects how genes are turned on, which has implications for the long-term development of children. Previous studies have focused on how the characteristics and individual genetics of a particular child in interaction with the experiences of the child in an effort to understand how health problems emerge. In the new study, researchers were able to measure the degree to which genes were turned "on" or "off" by a biochemical process called methylation. This new technique reveals ways that promote nature changes is how our social experiences can change the underlying biology of our genes.

The study, researchers from the University of Wisconsin, Madison, appears in the journal child development . Nearly 1 million children in the US are abused or neglected each year.

The researchers found an association between the type of parenting and children had a particular gene (called the glucocorticoid receptor gene) is responsible for crucial aspects of social functioning and health. all genes are not active at all times. DNA methylation is one of the biochemical mechanisms that cells use to control whether the genes are activated or deactivated. The researchers examined DNA methylation in blood from 56 children aged 11 to 14. Half of the children were physically abused.

They found that, compared to children who had not been abused, maltreated children had increased methylation at several sites of the glucocorticoid receptor gene, also known as NR3C1, echoing the results of studies earlier rodents. In this study, the effect took place on the section of the gene that is essential for nerve growth factor, which is an important part of healthy brain development.

There were no differences in genes that children are born with, the study revealed; however, differences were observed in the extent that the genes have been activated or deactivated. "This link between stress and life changes early genes can discover how early childhood experiences get under the skin and confer a lifetime risk," notes Seth D. Pollak, professor of psychology and pediatrics at the University of Wisconsin, Madison, who led the study.

Previous studies have shown that children who have experienced physical violence, sexual abuse and neglect are more likely to develop mood, anxiety and aggressive disorders, as well as having control problems of their emotions. These problems, in turn, can disrupt relationships and affect school performance. Abused children are also at risk of chronic conditions such as heart disease and cancer. The current study helps to explain why these childhood experiences can affect health later years.

The gene identified by researchers affects the (HPA) hypothalamic-pituitary-adrenal axis in rodents. Interruptions of this system in the brain it would be difficult for people to adjust their levels of behavioral and emotional stress. Circulating through the body in the blood, this gene affects the immune system, leaving people less able to fight germs and more vulnerable to disease.

"Our finding that children who were physically abused display a specific change in the glucocorticoid receptor gene could explain why abused children have more emotional problems as they age," according to Pollak. "They may have fewer glucocorticoid receptors in their brain, impairing brain stress-response system and cause stress regulation problems."

The results have implications for the design of more effective interventions for children, especially since animal studies indicate that the effects of bad parenting on gene methylation may be reversible if the benefit care improves. The study also adds to what we know about how child abuse concerns changes in the body and mind, the results that were recently summarized in a SRCD Report on Social Policy Sara R. Jaffee and Cindy W. Christian.

Monday, March 17, 2014

surgical biopsies can be performed safely in selected patients with lung cancer at an advanced stage

Tags
surgical biopsies can be performed safely in selected patients with lung cancer at an advanced stage -

Researchers at UC Davis have determined that surgical biopsies can be performed safely in certain patients Lateran stage non-small cell lung cancer, which should improve access to drugs that target specific genetic mutations, such as the receptor for epidermal growth factor (EGFR).

results, which will be published in the July issue of The Journal of Thoracic and Cardiovascular Surgery addresses a common problem in the treatment of advanced lung cancer :. insufficient tumor tissue available for molecular analysis, which is necessary before prescribing a targeted therapy

"We will allow more people to qualify for clinical trials, and ultimately that will provide value to the patient and access to treatment, they may not have had otherwise, "said the lead author of the study David T. Cooke, Associate Professor and head of the general thoracic surgery at UC Davis Medical Center.

In many cases of lung cancer at an advanced stage, the surgical biopsy is considered too dangerous, so the less invasive approaches are used, including fine needle aspiration and biopsies.

"With clinical trials of new targeted therapies, an exhausting level of testing is done," said Cooke. "With less invasive biopsies, sometimes the volume of collected cells are inadequate to the molecular test."

Cooke and colleagues retrospectively reviewed the records of 25 patients whose cases were reviewed at a conference of the multidisciplinary thoracic oncology clinic and who had known cancer or non-small cell lung stage IV suspected. All elected for surgical biopsies, most of which were made using the thoracic video-surgery, a procedure that requires general anesthesia, but only small incisions

Among the cases, five experienced a complication. three of them were minors. Surgical biopsy led to the identification of potentially targeted molecular information in 19 of 25 patients, and changed the treatment strategy in over half, with 10 of the 25 also determined eligible for listing in one trial targeted therapeutic clinic.

"patients who were examined in a multidisciplinary way and for whom less invasive biopsies are not likely to be successful, may be appropriate for a surgical biopsy, even in stage IV," concluded Cooke.

Cooke stressed that the approach should be used when the case was examined by a team of experts, including a pulmonologist, radiologist, surgeon and medical oncologist, and the best biopsy strategy is selected.

"I think this will change the game," he said. "It will allow thoracic surgeons to work closely with the multidisciplinary tumor boards and be participative in the care of patients lung cancer end of the line."

Sunday, March 16, 2014

University of Louisville researchers take a step forward in the fight against lung cancer

Tags
University of Louisville researchers take a step forward in the fight against lung cancer -

Researchers at the University of Louisville have discovered a group of small molecules that tell certain proteins to kill lung cancer cells. The team, led by Chi Li, Ph.D., Assistant Professor of Medicine, published their findings in the April 2014 issue of molecular and cell biology.

One of the characteristics of lung cancer is the deregulation of apoptosis, or controlled cell death. Cancer cells are able to survive in the abnormal state.

The proteins of the Bcl-2 family are key regulators of apoptosis. One of them, Bax, sometimes becomes erratic and loses its ability to maintain its killer function, which leads to the development of the lung tumor. The researchers realized that this meant Bax could be part of the cure as well.

The researchers used virtual screening in their study, a process where they ran through all possible combinations computer program molecules that could bind with the protein Bax to find the best combination. After trying more than 10 million molecules, they found the right one. This small molecule compound Bax activation kills lung cancer cells and inhibits the growth of lung tumors transplanted into mice.

The scientific discovery of Li and his team showed that it is possible to identify small molecules capable of binding and activation of Bax proteins that in turn induce apoptosis in cancer cells . In the study, Li and his team were able to specifically induce tumor cell death while avoiding normal cell death.

The compound also demonstrates synergy with carboplatin widely used chemotherapeutic drug. This means that the potential application of this compound in the treatment of cancer is very broad.

The scientific discovery could form the basis of advanced therapeutics for cancer patients, particularly lung cancer, which is particularly prevalent in Kentucky.

The high mortality rate of lung cancer is partly due to ineffective therapeutic treatments. This makes it very important for scientists to develop new chemotherapeutic drugs for lung cancer.

Li said it could open the way to new treatments for other types of cancer as well. "Lung cancer is a very big problem for us. We have a high mortality rate, and this is one of the reasons we wanted to go after lung cancer," he said. "We are trying to extend the application of our discovery of different types of cancer. "

Li and his team have the opportunity to expand this very soon. the National Institutes of Health recently awarded them a grant of $ 1.5 million to continue their innovative research.

Saturday, March 15, 2014

Helsinn Group grants rights Gen ILAC for Turkey

Tags
Helsinn Group grants rights Gen ILAC for Turkey -

The exclusive distribution and licensing agreement for the commercialization of Helsinn currently has in development for the anorexia- treatment of cachexia syndrome cancer in non-small lung cancer (NSCLC) patients

Helsinn Group, the company focused on strengthening quality care against cancer, today announces the rights to Anamorelin, its receptor agonist innovative ghrelin, have been granted to Turkey for Ilaç GEN.

Anamorelin is a novel pioneering oral drug, once daily in development for the treatment of cancer anorexia-cachexia syndrome ( "CACS"). The current phase III studies are designed to evaluate the safety and efficacy in increasing body weight, lean body mass, muscle strength, and patient quality of life. The main objective of the studies is non-small lung cancer and is almost complete.

Under the terms of the agreement, Helsinn will retain all development activities (chemistry, manufacturing and controls, preclinical and clinical) and supply of Anamorelin for commercial use. GEN Ilaç will be responsible for regulatory approval and commercial activities in their territories

Riccardo Braglia, CEO of Helsinn group, said :. "We are excited to take our first important step towards Turkey Anamorelin with a company with the reputation and reach of GEN Ilaç. Drugs like Anamorelin, targeting important therapeutic areas of unmet need such as CACS, will help improve the quality of life of patients living with cancer and help us achieve our goal of becoming the world leader in cancer supportive care company "

Gülmüs Abidin, CEO of GEN Ilaç added:" We are .. proud of our reputation as a leading specialty pharmaceutical companies in Turkey and we are delighted to have a successful partnership with Helsinn We look forward to providing Anamorelin oncologists for the treatment of patients with CACS. "

Friday, March 14, 2014

supplement herbal can become dangerous when taken with prescribed medications

Tags
supplement herbal can become dangerous when taken with prescribed medications -

St. John's wort, the first alternative and complementary treatment for depression in the States States, can be dangerous when taken with many commonly prescribed drugs, according to a study by researchers at Wake Forest Baptist Medical Center.

The researchers reported that the supplement herbal can reduce the concentration of many drugs in the body, including oral contraceptives, anticoagulants, cancer chemotherapy and blood pressure medications, resulting disabilities effectiveness and treatment failure.

"patients may have a false sense of security with the so-called" natural "treatments such as St. John's wort," said Sarah Taylor, MD, assistant professor of dermatology at Wake Forest Baptist and author principal of the study. "and it is crucial that doctors know about the dangers of" natural "treatments and communicate the risks to patients effectively."
the study is published in the current online issue of the alternative and complementary medicine Journal .

to determine how often the must of St. John (SJW) has been prescribed or taken with other drugs, the team process a retrospective analysis of representative national data collected by the National Survey of Ambulatory medical care from 1993 to 2010. the research team has discovered the use of hypericum in potentially harmful combinations in 28 percent of cases examined .

possible drug interactions may include serotonin syndrome, a potentially fatal disease that causes high levels of serotonin, a chemical to build up in your body, heart disease due to impaired efficiency medicines for blood pressure or an unplanned pregnancy due to contraceptive failure, Taylor said.

Limitations of the study are that only medicinal products registered by the doctor were analyzed. However, she indicated that the rate of SJW interactions may actually be underestimated because the database does not include patients who used SJW but did not tell their doctor.

"The labeling requirements for useful supplements such as St. John wort need to provide appropriate warnings and risk information," said Taylor, adding that France banned the use of St. John's wort products and several other countries, including Japan, the UK and Canada are in the process of including the interaction drug-herb warnings on products St. John wort.

"physicians must be trained to always ask if the patient takes supplements, vitamins, minerals or herbs, especially before prescribing any of the common drugs that can interact with St. John's wort. "

Thursday, March 13, 2014

Mayo Clinic Researchers find 31 genes key to clear renal cell carcinoma

Tags
Mayo Clinic Researchers find 31 genes key to clear renal cell carcinoma -

A genomic analysis of clear cell renal cell carcinoma (ccRCC), the most common form of cancer kidney, from 72 patients found 31 genes that are essential for the development, growth and spread of cancer, say researchers at Mayo Clinic in Florida. Eight of these genes has not been previously linked to renal cancer, and six other genes have never been known to be involved in all forms of cancer.

Their study, in the journal Oncotarget , is the most comprehensive analysis to date of the role of gene expression in tumor growth and metastasis ccRCC. The ccRCC subtype accounts for 80 percent of all cases of kidney cancer.

This study is a comprehensive analysis, because the overexpressed genes were functionally tested in kidney cancer cells to ensure that they were important to certain aspects of the cancer process, said study investigator higher, molecular biologist, John A. Copland, Ph.D.

"the power of this study is that we looked at the genes found to be overexpressed in tumors of patients and determined their function in cancer kidney, which was not done on a large scale before, "he said. "This is a decisive step in identifying key pathways and molecules involved in kidney cancer so that specific therapies that target these new genes can be developed to treat this cancer."

This kidney cancer is one of the top 10 solid cancers in the United States researchers expect 60,000 new cases diagnosed this year, with 13,000 deaths. Although the prognosis for kidney cancer that has not spread is good, patients with advanced or metastatic cancer will develop resistance to drugs. Patients with the untreated metastatic disease have a overall survival rate at five years of less than 10 percent.

The research team, which includes Mayo graduate student and lead author Christina von Roemeling, has already published several studies identifying some of the genes they found in genetic analysis. Considering the importance of these findings for patients, they decided to publish all the genes in both Oncotarget .

"We publish these findings to the scientific community so that effort can be mounted to know more about these genes and how they can be effectively targeted," says Dr. Copland. "We have patients quick search that focuses on new treatments to save lives. "

Targeted therapies currently used to treat kidney cancer are often toxic, he added.

"The study results represent a very major advance in the identification of therapeutic targets for ccRCC and open new avenues for the discovery and development. Of new therapeutic agents acting on these new drug targets should make a significant improvement in prognosis of ccRCC patients, "says co-author and Mayo oncologist Han Tun, MD

the researchers examined an equal number of samples (72) of kidney cancer and kidney tissues normal. They looked overproduction and under-expression of the RNA of the tissue, as well as proteins because genes express RNA to produce the protein. They found nearly 6,000 genes that fit this description. They isolated and tested 195 genes that are consistently higher in patient samples. The researchers then narrowed the "hit" list 31 after they tested each in cancer cells alive to see if these genes have contributed to the growth or spread of the tumor.

"We also found genes with other functions that are key to the survival of kidney cancer, such as inflammation. Found another gene is linked to angiogenesis, the production of new blood vessels to support tumor. This is a new discovery, "said von Roemeling." It is particularly important because ccRCC is well known to be a very angiogenic cancer.

"In addition to the potential of these genes and gene products to help us design new drugs, they could also serve as biomarkers for accurate diagnosis," she said. "It really is a treasure for future research on kidney cancer. "

Wednesday, March 12, 2014

Highmark, Horizon issued positive coverage policies for Afirma Gene Expression Classifier

Tags
Highmark, Horizon issued positive coverage policies for Afirma Gene Expression Classifier -

Veracyte, Inc., a molecular diagnostics company pioneering the field of molecular cytology, has announced today that two blue Cross blue Shield (BCBS) organizations affiliated to the Highmark, Inc. and Horizon blue Cross blue Shield of New Jersey, have issued positive coverage policies for the company Afirma ® Gene Expression classifier (GEC). The two companies have classified the genomic test medically necessary for use in the assessment of thyroid nodule fine needle aspiration (FNA) biopsies that are indeterminate after traditional cytopathology examination

and Highmark BCBS Horizon are among four organizations -affiliées -. Including Wellmark Blue Cross and Blue Shield and Premera Blue Cross - recently issued to positive coverage decisions for Afirma GEC. Highmark is 4 million lives and Horizon represents 3.6 million, bringing the total number of lives covered by BCBS Veracyte genomic test to over 10 million. The policies will be effective for these organizations from 1 September 2014 and 26 July 2014 respectively. The Afirma GEC is now covered for more than 135 million lives throughout the country.

"These positive coverage decisions by Highmark and Horizon further demonstrate the compelling value that the expression classifier Afirma Gene offer to patients, health professionals and insurers," said Bonnie H. Anderson, President and CEO of Veracyte. "Our test helps patients avoid unnecessary surgeries, while reducing health care costs. We are very pleased that this will now be available to over 10 million members of Blue Cross and Blue Shield. "

The Afirma GEC is the only molecular test refereed, published data showing that meets the performance criteria for inclusion in the National Comprehensive Cancer Network (NCCN), UpToDate® and preliminary guidelines American Thyroid Association - to allow patients with indeterminate results cytopathology and benign Afirma GEC opting for routine monitoring instead of the diagnostic surgery.

Veracyte offers Afirma Gene Expression classifier (GEC) as part of its Afirma thyroid FNA analysis. This comprehensive solution combines expert cytopathology assessment of thyroid nodule FNA samples with expression classifier Afirma Gene, genomic test used to identify thyroid benign nodules among those deemed inconclusive based on cytopathology. The company recently added its Afirma malignancy classifiers - genomic tests for medullary thyroid cancer and mutation of the BRAF gene. - To help guide the surgical strategy for patients who require surgery

Tuesday, March 11, 2014

Battelle acquires almost 11% of the outstanding Common Stock AMIC

Tags
Battelle acquires almost 11% of the outstanding Common Stock AMIC -

Advanced Medical Isotope Corporation ( "AMIC") (OTCBB: ADMD), a development company late stage mainly engaged in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, announced today that Battelle, acquired approximately 11% of the outstanding Common Stock AMIC. Battelle is a global science and technology leading company that explores emerging areas of science and develops and markets technologies

In 2011, AMIC has entered into licensing agreements with Battelle for 10 patents related to Amics products brachytherapy. and in 2012, AMIC has entered into an exclusive license agreement with Battelle for the use of brachytherapy patented gel technology Battelle

AMIC CEO and Chairman James C. Katzaroff said :. "Joint marketing effort AMIC and Battelle was recognized nationally in 2013 when AMIC received the Federal Laboratory Consortium Award for Excellence in Technology Transfer, a prestigious honor recognized by the US Secretary of energy and US Senator Patty Murray. We continue our close collaboration with Battelle and look forward to the commercialization of this exciting technology. "

Battelle acquired its interest in AMIC converting a previous note for partial review of studies conducted at PNNL. Details are presented in the form of the Company 8K filed with the Securities and Exchange Commission.

As previously announced, AMIC is in the process of obtaining approval from the FDA for its brachytherapy device Y-0 RadioGel ™. AMIC as recently announced, the FDA determined that the brachytherapy RadioGel ™ product is a medical device class III unless reclassified as a Class II device. This determination is being revised and the AMIC steps should be taken for approval. AMIC is engaged in discussions with the FDA in the pre-bid process, including a meeting in person.

Monday, March 10, 2014

The study finds no association between vaccination against HPV and increased risk of blood clot

Tags
The study finds no association between vaccination against HPV and increased risk of blood clot -

Although some data have suggested a potential association between receiving the quadrivalent human papillomavirus (HPV) and venous thromboembolism subsequent vaccination (VTE; blood clot), an analysis that included more than 500,000 women who received the vaccine did not find an increased risk of VTE, study says published in the July issue 9 JAMA [

"security problems can undermine immunization programs at the expense of public health, and timely assessments of these concerns are essential "the authors write.

Nikolai Madrid Scheller, MB, of the Statens Serum Institut, Copenhagen, Denmark, and colleagues used data from Danish national registries to assess the potential link between HPV vaccination quadrivalent and VTE. Information on vaccination, use of oral contraceptives, use of anticoagulants (blood thinners), and the result of a first diagnosis of VTE in the hospital are not related to pregnancy, surgery, or cancer was obtained from the Danish registers.

The study included all Danish women, aged 10 to 44 years, from October 06 to July 2013 (n = 1,613,798), of which 500,345 (31 percent) who received the quadrivalent vaccine against HPV ; there were 4,375 incident cases of VTE. Of these, 889 women (20 percent) were vaccinated during the study period. Data analysis did not find an association between the quadrivalent vaccine against HPV and VTE during the 42 days after vaccination (defined as the main risk period).

"Our findings, which were consistent after adjusting for the use of oral contraceptives and among girls and young women, and women mid-adult, do not provide support to an increased risk of VTE after the quadrivalent HPV vaccination, "the researchers write.

Saturday, March 8, 2014

Sheffield Hallam University is launching an online course Improve Prostate Cancer

Tags
Sheffield Hallam University is launching an online course Improve Prostate Cancer -

Sheffield Hallam University has joined the fight against one of the largest UK cancer killers throwing his first Massive Open online Course (MOOC) in Improving prostate cancer.

in collaboration with prostate cancer in the UK the MOOC was designed to give healthcare professionals, patients, caregivers, and those who have a keen interest in health, luck broaden their expertise and improve their knowledge of prostate cancer.

More than 40,000 new cases of prostate cancer are diagnosed every year and the University and the charity has developed the five-week program to cover key areas such as diagnosis, treatment, care and survival in later life.

The course is open to health professionals, students, patients and caregivers. It will be delivered in collaboration with the e-portfolio system, PebblePad via an interactive workbook online, discussion forums and live webinars with Sheffield Hallam University, specialists and guest speakers provided by prostate cancer in the United United.

Registration is now open for the free course which will begin on October 13, 2014. This will be the first time that the University has established a MOOC to its wide range of courses.

David Eddy, head of MOOC courses and keynote speaker of radiotherapy and oncology at the University of Sheffield Hallam, said: "This is a first for Sheffield Hallam and prostate cancer in the United -um It is designed to support and enable people around the country. and outside the UK, to study or improve their knowledge of prostate cancer care.

"Not only the current support and facilitate learning, it will also provide a forum for healthcare professionals, patients and carers to share information and discuss ways to improve the treatment of prostate cancer.

"The course has been designed and will be delivered by academics from Sheffield Hallam world class that will provide a high quality and engaging learning experience online with our other programs."

Gemma Borwick, education director for prostate cancer in the UK said: "More than 40,000 men are diagnosed each year with prostate cancer in the UK and it is fast become the most common cancer overall in 2030. as a result, it is more important than ever that health professionals are equipped with the right knowledge and skills to diagnose, treat and support of men with the disease.

"We are delighted to work with Sheffield Hallam University to its first MOOC to improve prostate cancer. It is a great opportunity for healthcare professionals and students to deepen their knowledge disease and learn about the latest treatments and supportive services to men living with prostate cancer. "

To register for a place on the MOOC visit http: //tinyurl.com/epccmooc or contact David Eddy via d.eddy@shu.ac.uk for more information

Friday, March 7, 2014

New knowledge can develop treatments for lung cancer patients

Tags
New knowledge can develop treatments for lung cancer patients -

The study of the most common form of lung cancer, researchers have found mutations in a cell signaling pathway that plays a role in forming tumors. The new knowledge may develop treatments for patients because drugs targeting some of these genetic changes are already available or are in clinical trials.

Reports July 9 in Nature , investigators from the Cancer Genome Atlas (TCGA), including researchers from the Washington University School of Medicine in St. Louis, and Harvard Medical School other institutions, studied tumors from 230 patients with lung adenocarcinoma.

"This is the first time we had a panoramic look at the genomic landscape of the many lung tumor samples," said oncologist Ramaswamy Govindan, MD, professor of medicine at the University Washington TCGA project lung cancer co-president. "These studies reinforce the view that lung cancer is a very heterogeneous disease."

Combined with a previous study of 178 patients lung squamous cell carcinoma, the TCGA researchers now have published genetic data on 400 patients with lung cancer and are working to analyze 0 more. tumors investigators included scientists from the University of the genomics Institute Washington and other major sequencing centers.

in the new study, among the myriad genetic changes observed in adenocarcinoma, a cell signaling pathway stood out. About 75 percent of the samples had mutations that an overactive pathway called RTK / RAS / RAF, known for her roles in tumor growth.

"It is remarkable that the importance of channel RTK / RAS / RAF seems to be," said Govindan, who treats patients at Siteman Cancer Center at Barnes-Jewish Hospital and University School of Medicine in Washington. "Mutations in this particular way promote cancer cell growth. What is amazing is how many ways this path can be activated.

" We know these tumors are not static, "he added. " They evolve. We should be looking at multiple biopsies over time to see how tumor cells escape by inhibiting a pathway and become resistant to treatment. "

The researchers also found other relevant mutations in important genes such as EGFR NF1 NF2 and MET . These results could be useful in a clinical trial known as ALCHEMIST (adjuvant Lung Cancer enrichment marker identification and trial sequencing) that directs Govindan. the trial will involve the screening of tumors thousands of lung cancer patients for gene alterations called EGFR and ALK . After surgery to remove their tumors, these patients will be invited to participate in clinical trials that study drugs targeting these genes dysfunctional.

ALCHEMIST's trial is based on the current study and will also potentially provide additional tumor samples for genomic analysis. A large sample size is important in the accurate identification of mutations that stimulate the growth of the tumor of the lung.

"Lung cancer patients often have substantial exposure to tobacco, which leads to a large number of mutations," said Govindan. "We can not be able to find important mutations unless we examine several samples from thousands of patients."

Despite these advances in lung cancer understanding - the most common cause of cancer death in the world - the researchers point out that the best way to reduce lung cancer deaths is to help people quit smoking and encourage others to never start.

Thursday, March 6, 2014

First edition July 11, 2014

Tags
First edition July 11, 2014 -

Today the titles include coverage surveys that offer a glimpse of how the health law is being to do in terms of reducing the nation's uninsurance rate [

Kaiser Health News: A reader asks: Is selling your house affect eligibility for Assisted Living
Kaiser Health consumer news columnist Michelle Andrews answers the question of this player (7/11) ?. Read his response

Politico. The verdict is in: Obamacare uninsured Lowers
A survey by the Commonwealth Fund found that 9.5 million fewer adults are now insured at the start of the Obamacare enrollment season. The Health Reform Monitoring Survey of the Urban Institute found a similar decline, with 8 million adults get coverage. Gallup-Healthways survey and reported that the uninsured rate declined to 13.4 percent of adults, the lowest level since it began tracking the health coverage in 08. That was all on Thursday. In recent months, other surveys of Gallup series have always found the same downward trend, and a RAND survey in April found that the law has extended health coverage to 9.3 million Americans (Näther, 7 / 11).

Los Angeles Times: Covers health law at least 8 million
The health care law President Obama has reduced the number of uninsured adults from 8 million to 11 million in its first year, according to three new studies, and satisfaction of the report of the majority of their new health plans. The studies -; made separately by the Commonwealth Fund, the Urban Institute and the Gallup organization -; use different methods to estimate the effect that the Affordable Care Act was (Terhune and Lauter, 7/10)

Los Angeles Times :. Californians uninsured rate is halved Under Obamacare, survey reveals
The percentage of Californians without health insurance has been cut in half over the last nine months during the expansion of the coverage of the federal law on health, a new study shows. Nationwide, an estimated 9.5 million adults aged under 65 have gained health insurance between the end of summer 2013 and last month, according to a survey by the Commonwealth Fund on Thursday released (Terhune, 7/10)

Politico :. More signs that health coverage grows in Obamacare
millions of Americans won since Obamacare health insurance took effect, according to several new surveys show that the law reduced the rate of the nation after uninsurance " train wreck "of a departure. Three new surveys published in rapid succession Thursday found a significant number of newly insured adults. None of these results will put to rest the political debate on the cost structure and the wisdom of the Affordable Care Act, but they only give firm defenders proof that the law respects the coverage targets (Wheaton, 7/10 ).

The New York Times: Suit against Obama to focus on the health care law, Boehner said
the trial of President John A. Boehner against President Obama will focus on changes to the Law on healthcare Mr. Boehner said should be left to Congress, according to a statement released Thursday by the office of the speaker (Weisman, 7/10)

Los Angeles Times :. House Lawsuit Over Obamacare to Focus On Employer Mandate Delay
House leaders announced Thursday that their trial planned against President Obama would focus on its inability to enforce the provisions of the Affordable Care Act, renew a fight on the right of the landmark health. Speaker John A. Boehner had already announced its intention to prosecute the president on what he said was Obama's failure to meet its constitutional obligations, but Boehner did not specify that the challenge would be based on (Memoli, 7/10).

Washington Wire The Wall Street Journal: Republicans Lay Out Legislation Room lawsuit against Obama
trial Speaker John Boehner of (R., Ohio) expected to challenge the executive actions of President Barack Obama will focus on the decision of the white House to waive the affordable Care Act mandate employer without the consent of Congress, Republican leaders Thursday. Republicans unveiled a proposed House resolution that would allow the House of Representatives to file a complaint against Mr. Obama, which is provided in the chamber to vote on this month. Mr. Boehner said the trial would be about the distribution of powers between the executive and the legislature, saying that the decision of the White House to change the health law violated the separation of powers (Crittenden, 7 / 10).

Politico: Obama continuing the GOP to devote to the employer mandate
House Republicans will base their lawsuit against President Barack Obama on "unilateral" decision of the administration to delay making provision of office of the employer in Obamacare, Speaker John Boehner said Thursday. Chairman of the Rules Committee Pete Sessions (R-Texas) issued a draft resolution that would allow the House to go forward with a case against Obama for House Republicans characterize as a wide abuse of executive power. The resolution will be considered by the committee next week and a vote on the House floor is expected by the end of July (French, 7/11)

The New York Times :. Obscure rule Restricted extension of the Health Law Care For Addicts
law allowed states to extend Medicaid to many more low-income people, which means that addicts and alcoholics who were previously ineligible may now receive coverage for the treatment of drug addiction, the law was considered an "essential health benefit". But there's a catch :. Under an obscure federal rule promulgated there nearly 50 years, Medicaid covers residential addiction treatment in community-based programs if they have 16 or fewer beds (Goodnough, 7/10)

the Washington post: Michigan reaches its health policy insurance registration 8 months ago
Michigan Governor Rick Snyder (R) announced Thursday that the state had achieved its goal of first year of signing up 322,000 residents of Michigan health Plan eight months earlier. Approximately 477,000 Michigan residents are eligible for the Plan of Michigan Health, Medicaid expanded state for low-income residents. . To be eligible, individuals can not qualify for or be enrolled in Medicare or Medicaid programs and others must have an income equal or less than 133 percent of the poverty line (Schwartz, 7/10)

the Wall Street Journal: Dr. Quitte-uterine device security panel on the conflict
a member of a panel advising the government on the safety of a medical device that can spread the cancer women resigned after the Food and Drug administration of the United States considered the advisory fees received from an equipment manufacturer, the agency said Thursday (Levitz, 7/10)

Washington post:. FDA Free-Speech, security issues to weigh Review Of 'Off-Label' Drug Marketing
Driven in part by the recent decisions of the Federal Court, the FDA reviews its rules on this type of pharmaceutical companies data should be authorized to distribute to doctors about off-label uses, and how they must respond to spontaneous questions from doctors about these uses. Its objective is to issue new guidelines by the end of the year (Dennis, 7/9)

Los Angeles Times :. UnitedHealth Group Sues Over California Fine
Establishment of a major legal battle, UnitedHealth Group Inc. sued the insurance commissioner of California to block his attempt to fine the insurer $ 173.6 million for violations during an acquisition sloppy 05. The lawsuit, filed Thursday in Orange County Superior Court, is the latest twist in a long political drama. There are four years, California has asked for a jaw-dropping fine of almost $ 10 billion against UnitedHealth, the largest health insurer in the nation. The penalty to handling problems of medical claims and policy applications after the insurer bought PacifiCare, based in Cypress (Terhune, 7/10)

The Associated Press: Changes Regs on Va .. long-term care insurance
Virginia regulators encourage long-term care policyholders to take advantage of changes that strengthen the protection against accidental cover failures due to non-payment. The Corporation Commission State Insurance Bureau said insurers have long been required to provide the insured with the possibility to appoint a third party to receive notice of forfeiture of the impending policy (7/10).


http://www.kaiserhealthnews.org This article has been reprinted kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a professional health policy research non-partisan organization affiliated with Kaiser Permanente.

Wednesday, March 5, 2014

Study reveals why the survival of patients with blood cancer still varies between regions in Europe

Tags
Study reveals why the survival of patients with blood cancer still varies between regions in Europe -

Failure to obtain the best treatment and changes in the quality of care are the most likely reasons why survival for patients with blood cancer still varies widely between the regions of Europe, according to the largest study population-based survival among European adults to date , published in The Lancet Oncology .

"the good news is that survival at 5 years for most cancers of the blood has increased over the past 11 years, most likely reflecting the approval of new targeted drugs in the early 00s, as rituximab for non-Hodgkins lymphoma and imatinib for chronic myeloid leukemia, "said study leader Dr Milena Sant Fondazione IRCCS Istituto the Nazionale dei Tumori in Milan, Italy.

"But there are still persistent differences between regions. For example, the absorption and utilization of new technologies and therapies was much slower in Eastern Europe than other regions. This may have contributed to the great differences in management and patient outcomes. "

The Eurocare study analyzed data from 30 cancer registries covering all patients diagnosed in 20 European countries to compare changes in the 5-year survival for more than 560,400 adults (aged 15 and over ) 11 diagnosed with lymphoid and myeloid cancers between 1997 and 08 and followed until the end of 08.

Certain blood cancers showed particularly large increases in survival between 1997 and 08, for example, follicular lymphoma (59% to 74%), diffuse large B-cell lymphoma (42% to 55%), chronic myeloid leukemia (32% to 54%) and acute promyelocytic leukemia (50% to 62%).

the greatest improvements in survival during 1997-08 were in northern, central and eastern Europe, although adults in Eastern Europe (where survival in 1997 was the lowest) continue to have lower survival for most blood cancers elsewhere.

But survival gains were lower in southern Europe and the UK. For example, improved 5-year survival of chronic myeloid leukemia in the north (29% to 60%) and Central Europe (34% to 65%) were consistently higher than in the UK (35 % to 56%) and in Southern Europe (37% to 55%). For more detailed results for all cancers by European area see Table 4 on page 6 and Figure 2 on page 6.

The risk of death within 5 years of diagnosis fell so significant for all malignancies, with the exception of myelodysplastic syndromes between 1997 and 08. But not all regions have seen such improvements. For example, compared to the UK, the excess risk of death was significantly higher in Eastern Europe than in other regions for most cancers studied, but significantly lower in Northern Europe. For more detailed results for all cancers in the European zone and age See Table 5 on page 7.

The authors suggest that the most likely reasons for continuing geographic differences in survival inequalities in the provision of care and the availability and use of new treatments.

"We know that rituximab, imatinib, thalidomide, bortezomib and were first made available for general use in Europe in 1997, 01, 1998 and 03 respectively. The years following mailing generally these drugs coincided with a sharp increase in the survival of chronic myeloid leukemia, diffuse large cell lymphoma B, and follicular lymphoma, with an increase in smaller but significant survival for multiple myeloma plasmacytoma "say. authors.

However, they emphasize that the absorption and use of these drugs has not been uniform throughout Europe. For example, rituximab absorption, imatinib and bortezomib market was lower in Eastern Europe and elsewhere could always explain the lower survival in this region

According Sant :.

High resolution studies using clinical records to collect detailed clinical information for representative samples of cancer registry can more directly link treatment and clinical characteristics of survival.

Write a comment linked, Alastair Munro of the University of Dundee Medical School in Scotland question whether these improvements in survival can be simply attributed to drugs, saying, "A better understanding the 5-EUROCARE findings require additional information on changes over time (and space) concerning: survival according to the broad categories of disease (Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, myeloma and other malignancies myeloid), distribution of histological subtypes and their relationship with the age distribution of the population; the phase distribution at diagnosis, and the time of active intervention for tumors indolent. ... in comparison, either in time or in space, one must consider the effect of potential confounding factors. is it all on drugs? the answer is, not quite. "